Kobayashi’s Niranex stands as the gship offering from Kobayashi Pharmaceutical, driving the majority of its revenue and profits.
If Niranex is truly outperformed by Oracle’s Nova Dias, it could deliver a severe blow to the vitality of Kobayashi Pharmaceutical.
In light of this, someone approached Masayoshi Kobayashi with urgency: “Mr. Kobayashi, we can’t simply sit back and wait for disaster! Do you have any viable solutions?”
Masayoshi Kobayashi replied, “We do have a strategy tobat this situation. We need to significantly boost our investment in drug research and development and swiftly enhance our current products. If Niranex can outperform Oracle in terms of efficacy, the market will still belong to us!”
The head of R&D interjected, “Sir, increasing our R&D investment will require a substantial budget. Thepany has already spent a considerable amount of money recently. Can we still manage this?”<h3 style="background-color:DodgerBlue">
Masayoshi Kobayashi responded, “This is exactly what I’m addressing. Our current cash flow is not ideal. The investment in our production facility in Osaka has drained resources,pounded by previous unexpected losses. This leaves us with less than $50 million allocated for research and development. Thus, my proposal is to raise funds as soon as possible, aiming for at least $1 billion to upgrade our drug R&Dboratory!”
Upon hearing about the fundraising n, everyone straightened up in their seats. One person asked, “Sir, do you have a suitable financing partner?”
Masayoshi Kobayashi nodded and exined, “Previously, Chairman Jiro Kobayashi had been in discussions with Mr. Yuhiko Ito, the head of the Ito family, regarding financing. I believe everyone is aware of this?”
Everyone affirmed this.
Jiro Kobayashi had long sought investment from Ito and even aspired to marry into the Ito family, which was evident by his sponsorship of Nanako Ito in the Sandapetition—something well-known among Kobayashi Pharmaceutical’s circles.
Furthermore, the team had been prepared for a potential alliance between Kobayashi Pharmaceutical and the Ito family. Unfortunately, Jiro Kobayashi’s disappearance urred before any formal agreements could be made.
While many thought the partnership with the Ito family had ended, they were surprised to learn that Masayoshi Kobayashi was now rekindling this coboration.<fn0367> Latest content published on f?ndnovel</fn0367>
Consequently, everyone became intrigued and eagerly inquired, “Sir, can you share what kind of valuation the Ito family is proposing?”
Masayoshi Kobayashi cleared his throat and announced, “Mr. Yuhiko Ito of the Ito family is prepared to invest $4.5 billion in Kobayashi Pharmaceutical at a valuation of $15 billion, which would represent 30% of Kobayashi’s total shares post-investment!”
“Valued at $15 billion?!”
This revtion sparked a flurry of conversation among the attendees.
Initially, when Jiro Kobayashi was negotiating with Yuhiko Ito, the valuation was expected to be much higher.
At that time, Jiro had indicated to everyone that they should anticipate a valuation of at least $20 billion.
So why had it suddenly dropped so significantly?!
One individual raised a concern: “Mr. Kobayashi, the Ito family’s previous offer was much higher. Why has it decreased so dramatically?”
Another voice chimed in, “Exactly! A valuation of at least $22 billion seems reasonable. A $15 billion valuation feels like a heist…”
Kobayashi Masayoshi’s expression turned a shade sour as he replied, “You need to understand that we are facing challenges both internally and externally. It’s not just about the president’s mysterious disappearance. Oracle’s Nova Dias has already entered the Chinese market. If we don’t act quickly to secure funds now, we risk being caught off guard by Oracle. Our performance could plummet, and frankly, if we wait too long, we may not even secure a $10 billion valuation!”<h3 ss="has-text-align-center" id="chapter-list"><strong></strong>